Digital Radiology Market by Component (Hardware, Services, Software), Deployment Mode (Cloud, On Premise), Application, End User - Global Forecast 2025-2032
Description
The Digital Radiology Market was valued at USD 10.78 billion in 2024 and is projected to grow to USD 11.97 billion in 2025, with a CAGR of 12.56%, reaching USD 27.80 billion by 2032.
A concise yet comprehensive orientation to the converging forces in digital radiology that prepare executive leaders for strategic decisions and operational alignment
The digital radiology landscape is undergoing a period of concentrated change driven by advances in imaging hardware, emergent software modalities, expanding services, and shifting care delivery models. This executive summary introduces the core dynamics shaping strategy and investment decisions, emphasizing how convergence across technologies and stakeholders is redefining clinical workflows and commercial approaches. It sets the stage for decision-makers by highlighting structural trends that demand integrated responses from manufacturers, healthcare providers, and technology vendors.
Across clinical and operational functions, the emphasis is increasingly on actionable imaging intelligence rather than siloed imaging modalities. Consequently, leaders must reorient priorities toward interoperable platforms, validated AI algorithms, and service models that reduce friction for adoption. This introduction also frames the role of regulatory change, supply chain resilience, and reimbursement shifts in shaping near‑term opportunities and risks. By establishing a strategic lens grounded in patient outcomes, fiscal stewardship, and technological feasibility, this section prepares executives for the deeper analyses that follow and underscores the urgency of proactive capability development.
How platform migration, AI integration, cloud and edge processing, and decentralized imaging are reshaping clinical workflows and commercial models across radiology
Digital radiology is transitioning from discrete equipment procurement to platform-centric imaging ecosystems, and this shift is exerting profound effects on clinical practice, procurement, and product strategy. Artificial intelligence has moved from proof‑of‑concept to embedded workflow augmentation, improving lesion detection and prioritization while also raising new validation, governance, and liability considerations. At the same time, cloud architectures and edge processing are decentralizing analytics, enabling faster turnaround at the point of care and facilitating collaboration across distributed networks of imaging sites.
Interoperability initiatives and standards adoption are making longitudinal imaging data more useful for longitudinal care pathways, while tele‑radiology and remote reading models are broadening the pool of diagnosticians and changing staffing economics. Moreover, design advances in detectors, transducers, and compact hardware are enabling portable and outpatient imaging, shifting utilization away from inpatient capital centers. As a result, vendors are evolving from single‑product companies into service and software platform providers, and providers are demanding outcome‑oriented contracts and performance guarantees. These transformative shifts require stakeholders to rethink R&D priorities, partnership models, and deployment strategies to sustain competitiveness and clinical impact.
Assessing the multilayered consequences of tariff measures on supply chains, procurement behavior, product strategies, and clinical deployment in radiology
The imposition of tariffs and trade measures has direct and indirect effects across the digital radiology value chain, influencing procurement practices, supply chain architecture, and product design decisions. Tariff pressures on imported components and finished imaging systems increase the effective cost of capital equipment for many providers, which in turn extends procurement cycles, drives demand for refurbished and service‑based models, and elevates interest in local assembly or supplier diversification. In addition, manufacturers respond by reassessing supplier contracts, qualifying alternative component sources, and, in some cases, shifting production footprints to mitigate tariff exposure.
Beyond immediate cost implications, tariffs catalyze strategic responses that affect innovation velocity and partnership structures. Vendors may prioritize software and subscription revenue streams that are less sensitive to cross‑border duties, while service organizations emphasize remote implementation and virtual training to preserve margin. Healthcare providers, particularly those operating networks across multiple jurisdictions, accelerate sourcing rationalization and long‑term maintenance agreements to stabilize service continuity. Regulatory compliance and clinical validation burdens compound these dynamics, prompting longer timelines for product rollouts and heightened emphasis on localized regulatory pathways and post‑market surveillance. Collectively, these shifts require a recalibration of risk models and capital planning for manufacturers, health systems, and investors alike.
Integrated segmentation insights that link component innovation, end‑user priorities, clinical applications, and deployment models to inform precise commercial strategies
Segment insights reveal where competitive and clinical tensions converge, and they offer guidance on prioritizing investment across product, user, clinical, and deployment vectors. By component, the market spans Hardware that includes detectors, magnets, transducers, and X‑ray tubes, Services that comprise consulting, installation and maintenance, and training and support, and Software that encompasses AI diagnostics software, picture archiving and communication systems, and radiology information systems. This composition means that innovations or disruptions in any single component category ripple across adjacent segments; for example, advances in detector technology increase the value of integrated AI diagnostics, while enhanced RIS/PACS interoperability raises vendor switching costs.
Considering end users, adoption patterns vary across ambulatory care centers, clinics, diagnostic imaging centers, and hospitals, with outpatient sites often prioritizing portability, cost efficiency, and rapid turnaround, and hospitals emphasizing enterprise integration, regulatory validation, and multi‑modal compatibility. Application focus areas such as cardiology, gastroenterology, neurology, oncology, and orthopedics drive differentiated requirements for resolution, contrast, and algorithmic support, which in turn affect product roadmaps and clinical validation priorities. Finally, deployment mode choices between cloud and on‑premise implementations shape procurement cycles, ongoing revenue models, and data governance responsibilities. Integrating these segmentation perspectives enables more targeted go‑to‑market strategies and clearer alignment between clinical needs and commercial offerings.
Regional market dynamics that emphasize differentiated regulatory, procurement, and adoption patterns across the Americas, EMEA, and Asia‑Pacific markets
Regional dynamics reflect distinct demand drivers, regulatory environments, and supply chain configurations that influence strategy and investment decisions. In the Americas, procurement momentum is tied to value‑based care initiatives, fiscal constraints in public systems, and a mature private market that emphasizes performance metrics and service level agreements. These factors favor bundled offerings and outcome‑oriented contracts, while also accelerating adoption of validated AI tools that can demonstrably improve throughput and diagnostic accuracy.
Across Europe, the Middle East & Africa, regulatory harmonization, data protection regimes, and disparate health infrastructure create a mixed landscape where centralized purchasing and regional distribution partners play crucial roles. Providers in this region often prioritize compliance, long‑term service agreements, and modular solutions that can bridge facility capabilities. In the Asia‑Pacific region, rapid hospital expansion, an emphasis on outpatient care, and growing local manufacturing capacity are driving demand for scalable, cost‑effective imaging solutions and cloud‑native deployments. Each region’s distinct regulatory cadence, reimbursement environment, and capital intensity calls for tailored commercial models, local partnerships, and appropriately sequenced product launches to ensure adoption and sustainable growth.
How successful vendors are combining AI integration, service diversification, supply chain resilience, and platform strategies to secure competitive advantage
Leading organizations are pursuing a range of strategic moves to strengthen competitiveness, focusing on platform consolidation, service expansion, and ecosystem partnerships. Many vendors are integrating AI capabilities directly into imaging suites and PACS/RIS workflows to create differentiated, outcome‑focused propositions, while others are forming alliances with cloud providers and systems integrators to accelerate deployment and reduce implementation friction. Service diversification, including managed services and performance‑based contracts, is becoming an increasingly important lever for stabilizing revenues and deepening customer relationships.
Manufacturers are rethinking supply chain resilience by qualifying secondary suppliers, investing in regional production capacity, and optimizing component design for easier localization. Software vendors are emphasizing regulatory conformity and clinical validation, investing in real‑world evidence generation, and seeking interoperability certifications that simplify hospital procurement. Meanwhile, several players are piloting subscription and usage‑based pricing to lower adoption barriers and support predictable lifetime revenue. These strategic priorities reflect an industry-wide recognition that sustainable advantage will accrue to organizations that can combine validated clinical performance with operational scale, flexible commercial models, and strong post‑sale services.
Actionable strategic playbook for vendors and providers that prioritizes validation, modular design, flexible commercial models, and supply chain resilience to accelerate adoption
Industry leaders should adopt coordinated strategies that emphasize clinical validation, modular platform design, and resilient supply chains to capture emerging opportunities. First, prioritize rigorous prospective validation and transparent performance reporting for AI algorithms to accelerate clinician confidence and payer acceptance. Simultaneously, design hardware and software as modular components that can be upgraded independently, enabling providers to extend asset lifecycles and align purchasing with clinical priorities. These moves reduce capital intensity and support incremental value delivery.
Next, restructure commercial approaches to include subscription and outcome‑based contracts that lower upfront costs for providers and align incentives around clinical performance. Invest in regional manufacturing partnerships or assembly nodes to mitigate tariff and logistics risk while preserving ability to meet local regulatory requirements. Strengthen post‑sale offerings by bundling maintenance, remote diagnostics, and training to improve uptime and clinical adoption. Finally, cultivate interoperable data strategies that prioritize standards compliance, robust cybersecurity, and seamless EMR integration to unlock longitudinal data use cases and support population health initiatives. Taken together, these recommendations balance near‑term operational resilience with strategic positioning for long‑term adoption and growth.
A rigorous mixed‑methods research approach combining expert interviews, evidence triangulation, and scenario analysis to ensure actionable and validated insights
The research underpinning this executive summary combines qualitative expert engagement with systematic evidence synthesis to ensure robustness and practical relevance. Primary inputs included structured interviews and consultations with clinical leaders, imaging engineers, procurement executives, and regulatory experts to surface operational constraints, adoption drivers, and validation priorities. These insights were triangulated with secondary sources such as peer‑reviewed literature, regulatory filings, product technical documentation, and publicly available clinical performance studies to validate claims and contextualize trends.
Analytical approaches included thematic coding of interview data, cross‑validation of vendor claims against published clinical evidence, and scenario analysis to explore the implications of policy shifts, trade measures, and technology maturation. Attention was paid to segmentation granularity across component, end user, application, and deployment axes, while regional analyses were informed by documented regulatory frameworks and infrastructure indicators. Throughout, findings were subject to internal peer review and methodological checks to reduce bias and ensure that conclusions are actionable for decision‑makers operating in diverse clinical and commercial contexts.
Concluding synthesis that ties together technology, validation, commercial strategy, and regional considerations to guide executive decisions in digital radiology
In conclusion, digital radiology occupies a pivotal role at the intersection of clinical performance, data science, and healthcare operations. The trajectory ahead will be shaped by how effectively stakeholders integrate AI into validated workflows, deploy modular and interoperable platforms, and adapt commercial and manufacturing models to evolving trade and regulatory realities. Strategic emphasis on clinical validation, service delivery, supply chain resilience, and regionally tailored go‑to‑market plans will determine which organizations convert technological potential into sustainable clinical and economic value.
Leaders should regard current market dynamics as an opportunity to reconfigure value propositions toward outcomes, not just capabilities. By aligning product roadmaps with clinician needs, investing in post‑market evidence, and pursuing flexible commercial models, organizations can reduce adoption friction and capture long‑term partnerships with health systems. The imperative now is to move deliberately from planning to pilot to scale, leveraging targeted investments and collaborations that both mitigate near‑term risk and establish durable competitive positioning in the evolving radiology ecosystem.
Please Note: PDF & Excel + Online Access - 1 Year
A concise yet comprehensive orientation to the converging forces in digital radiology that prepare executive leaders for strategic decisions and operational alignment
The digital radiology landscape is undergoing a period of concentrated change driven by advances in imaging hardware, emergent software modalities, expanding services, and shifting care delivery models. This executive summary introduces the core dynamics shaping strategy and investment decisions, emphasizing how convergence across technologies and stakeholders is redefining clinical workflows and commercial approaches. It sets the stage for decision-makers by highlighting structural trends that demand integrated responses from manufacturers, healthcare providers, and technology vendors.
Across clinical and operational functions, the emphasis is increasingly on actionable imaging intelligence rather than siloed imaging modalities. Consequently, leaders must reorient priorities toward interoperable platforms, validated AI algorithms, and service models that reduce friction for adoption. This introduction also frames the role of regulatory change, supply chain resilience, and reimbursement shifts in shaping near‑term opportunities and risks. By establishing a strategic lens grounded in patient outcomes, fiscal stewardship, and technological feasibility, this section prepares executives for the deeper analyses that follow and underscores the urgency of proactive capability development.
How platform migration, AI integration, cloud and edge processing, and decentralized imaging are reshaping clinical workflows and commercial models across radiology
Digital radiology is transitioning from discrete equipment procurement to platform-centric imaging ecosystems, and this shift is exerting profound effects on clinical practice, procurement, and product strategy. Artificial intelligence has moved from proof‑of‑concept to embedded workflow augmentation, improving lesion detection and prioritization while also raising new validation, governance, and liability considerations. At the same time, cloud architectures and edge processing are decentralizing analytics, enabling faster turnaround at the point of care and facilitating collaboration across distributed networks of imaging sites.
Interoperability initiatives and standards adoption are making longitudinal imaging data more useful for longitudinal care pathways, while tele‑radiology and remote reading models are broadening the pool of diagnosticians and changing staffing economics. Moreover, design advances in detectors, transducers, and compact hardware are enabling portable and outpatient imaging, shifting utilization away from inpatient capital centers. As a result, vendors are evolving from single‑product companies into service and software platform providers, and providers are demanding outcome‑oriented contracts and performance guarantees. These transformative shifts require stakeholders to rethink R&D priorities, partnership models, and deployment strategies to sustain competitiveness and clinical impact.
Assessing the multilayered consequences of tariff measures on supply chains, procurement behavior, product strategies, and clinical deployment in radiology
The imposition of tariffs and trade measures has direct and indirect effects across the digital radiology value chain, influencing procurement practices, supply chain architecture, and product design decisions. Tariff pressures on imported components and finished imaging systems increase the effective cost of capital equipment for many providers, which in turn extends procurement cycles, drives demand for refurbished and service‑based models, and elevates interest in local assembly or supplier diversification. In addition, manufacturers respond by reassessing supplier contracts, qualifying alternative component sources, and, in some cases, shifting production footprints to mitigate tariff exposure.
Beyond immediate cost implications, tariffs catalyze strategic responses that affect innovation velocity and partnership structures. Vendors may prioritize software and subscription revenue streams that are less sensitive to cross‑border duties, while service organizations emphasize remote implementation and virtual training to preserve margin. Healthcare providers, particularly those operating networks across multiple jurisdictions, accelerate sourcing rationalization and long‑term maintenance agreements to stabilize service continuity. Regulatory compliance and clinical validation burdens compound these dynamics, prompting longer timelines for product rollouts and heightened emphasis on localized regulatory pathways and post‑market surveillance. Collectively, these shifts require a recalibration of risk models and capital planning for manufacturers, health systems, and investors alike.
Integrated segmentation insights that link component innovation, end‑user priorities, clinical applications, and deployment models to inform precise commercial strategies
Segment insights reveal where competitive and clinical tensions converge, and they offer guidance on prioritizing investment across product, user, clinical, and deployment vectors. By component, the market spans Hardware that includes detectors, magnets, transducers, and X‑ray tubes, Services that comprise consulting, installation and maintenance, and training and support, and Software that encompasses AI diagnostics software, picture archiving and communication systems, and radiology information systems. This composition means that innovations or disruptions in any single component category ripple across adjacent segments; for example, advances in detector technology increase the value of integrated AI diagnostics, while enhanced RIS/PACS interoperability raises vendor switching costs.
Considering end users, adoption patterns vary across ambulatory care centers, clinics, diagnostic imaging centers, and hospitals, with outpatient sites often prioritizing portability, cost efficiency, and rapid turnaround, and hospitals emphasizing enterprise integration, regulatory validation, and multi‑modal compatibility. Application focus areas such as cardiology, gastroenterology, neurology, oncology, and orthopedics drive differentiated requirements for resolution, contrast, and algorithmic support, which in turn affect product roadmaps and clinical validation priorities. Finally, deployment mode choices between cloud and on‑premise implementations shape procurement cycles, ongoing revenue models, and data governance responsibilities. Integrating these segmentation perspectives enables more targeted go‑to‑market strategies and clearer alignment between clinical needs and commercial offerings.
Regional market dynamics that emphasize differentiated regulatory, procurement, and adoption patterns across the Americas, EMEA, and Asia‑Pacific markets
Regional dynamics reflect distinct demand drivers, regulatory environments, and supply chain configurations that influence strategy and investment decisions. In the Americas, procurement momentum is tied to value‑based care initiatives, fiscal constraints in public systems, and a mature private market that emphasizes performance metrics and service level agreements. These factors favor bundled offerings and outcome‑oriented contracts, while also accelerating adoption of validated AI tools that can demonstrably improve throughput and diagnostic accuracy.
Across Europe, the Middle East & Africa, regulatory harmonization, data protection regimes, and disparate health infrastructure create a mixed landscape where centralized purchasing and regional distribution partners play crucial roles. Providers in this region often prioritize compliance, long‑term service agreements, and modular solutions that can bridge facility capabilities. In the Asia‑Pacific region, rapid hospital expansion, an emphasis on outpatient care, and growing local manufacturing capacity are driving demand for scalable, cost‑effective imaging solutions and cloud‑native deployments. Each region’s distinct regulatory cadence, reimbursement environment, and capital intensity calls for tailored commercial models, local partnerships, and appropriately sequenced product launches to ensure adoption and sustainable growth.
How successful vendors are combining AI integration, service diversification, supply chain resilience, and platform strategies to secure competitive advantage
Leading organizations are pursuing a range of strategic moves to strengthen competitiveness, focusing on platform consolidation, service expansion, and ecosystem partnerships. Many vendors are integrating AI capabilities directly into imaging suites and PACS/RIS workflows to create differentiated, outcome‑focused propositions, while others are forming alliances with cloud providers and systems integrators to accelerate deployment and reduce implementation friction. Service diversification, including managed services and performance‑based contracts, is becoming an increasingly important lever for stabilizing revenues and deepening customer relationships.
Manufacturers are rethinking supply chain resilience by qualifying secondary suppliers, investing in regional production capacity, and optimizing component design for easier localization. Software vendors are emphasizing regulatory conformity and clinical validation, investing in real‑world evidence generation, and seeking interoperability certifications that simplify hospital procurement. Meanwhile, several players are piloting subscription and usage‑based pricing to lower adoption barriers and support predictable lifetime revenue. These strategic priorities reflect an industry-wide recognition that sustainable advantage will accrue to organizations that can combine validated clinical performance with operational scale, flexible commercial models, and strong post‑sale services.
Actionable strategic playbook for vendors and providers that prioritizes validation, modular design, flexible commercial models, and supply chain resilience to accelerate adoption
Industry leaders should adopt coordinated strategies that emphasize clinical validation, modular platform design, and resilient supply chains to capture emerging opportunities. First, prioritize rigorous prospective validation and transparent performance reporting for AI algorithms to accelerate clinician confidence and payer acceptance. Simultaneously, design hardware and software as modular components that can be upgraded independently, enabling providers to extend asset lifecycles and align purchasing with clinical priorities. These moves reduce capital intensity and support incremental value delivery.
Next, restructure commercial approaches to include subscription and outcome‑based contracts that lower upfront costs for providers and align incentives around clinical performance. Invest in regional manufacturing partnerships or assembly nodes to mitigate tariff and logistics risk while preserving ability to meet local regulatory requirements. Strengthen post‑sale offerings by bundling maintenance, remote diagnostics, and training to improve uptime and clinical adoption. Finally, cultivate interoperable data strategies that prioritize standards compliance, robust cybersecurity, and seamless EMR integration to unlock longitudinal data use cases and support population health initiatives. Taken together, these recommendations balance near‑term operational resilience with strategic positioning for long‑term adoption and growth.
A rigorous mixed‑methods research approach combining expert interviews, evidence triangulation, and scenario analysis to ensure actionable and validated insights
The research underpinning this executive summary combines qualitative expert engagement with systematic evidence synthesis to ensure robustness and practical relevance. Primary inputs included structured interviews and consultations with clinical leaders, imaging engineers, procurement executives, and regulatory experts to surface operational constraints, adoption drivers, and validation priorities. These insights were triangulated with secondary sources such as peer‑reviewed literature, regulatory filings, product technical documentation, and publicly available clinical performance studies to validate claims and contextualize trends.
Analytical approaches included thematic coding of interview data, cross‑validation of vendor claims against published clinical evidence, and scenario analysis to explore the implications of policy shifts, trade measures, and technology maturation. Attention was paid to segmentation granularity across component, end user, application, and deployment axes, while regional analyses were informed by documented regulatory frameworks and infrastructure indicators. Throughout, findings were subject to internal peer review and methodological checks to reduce bias and ensure that conclusions are actionable for decision‑makers operating in diverse clinical and commercial contexts.
Concluding synthesis that ties together technology, validation, commercial strategy, and regional considerations to guide executive decisions in digital radiology
In conclusion, digital radiology occupies a pivotal role at the intersection of clinical performance, data science, and healthcare operations. The trajectory ahead will be shaped by how effectively stakeholders integrate AI into validated workflows, deploy modular and interoperable platforms, and adapt commercial and manufacturing models to evolving trade and regulatory realities. Strategic emphasis on clinical validation, service delivery, supply chain resilience, and regionally tailored go‑to‑market plans will determine which organizations convert technological potential into sustainable clinical and economic value.
Leaders should regard current market dynamics as an opportunity to reconfigure value propositions toward outcomes, not just capabilities. By aligning product roadmaps with clinician needs, investing in post‑market evidence, and pursuing flexible commercial models, organizations can reduce adoption friction and capture long‑term partnerships with health systems. The imperative now is to move deliberately from planning to pilot to scale, leveraging targeted investments and collaborations that both mitigate near‑term risk and establish durable competitive positioning in the evolving radiology ecosystem.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence algorithms in digital radiology for automated anomaly detection and workflow optimization
- 5.2. Adoption of cloud-based PACS platforms to enable remote image storage and real-time collaborative diagnostics
- 5.3. Development of portable digital radiography devices with enhanced image quality for point-of-care and field use
- 5.4. Implementation of advanced 3D imaging and reconstruction techniques for improved diagnostic precision and surgical planning
- 5.5. Utilization of deep learning models for predictive analytics in radiology to anticipate patient outcomes and optimize care paths
- 5.6. Expansion of tele-radiology services supported by secure high-speed networks and regulatory compliance measures
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Digital Radiology Market, by Component
- 8.1. Hardware
- 8.1.1. Detectors
- 8.1.2. Magnets
- 8.1.3. Transducers
- 8.1.4. X-Ray Tubes
- 8.2. Services
- 8.2.1. Consulting
- 8.2.2. Installation And Maintenance
- 8.2.3. Training And Support
- 8.3. Software
- 8.3.1. Ai Diagnostics Software
- 8.3.2. Picture Archiving And Communication Systems
- 8.3.3. Radiology Information Systems
- 9. Digital Radiology Market, by Deployment Mode
- 9.1. Cloud
- 9.2. On Premise
- 10. Digital Radiology Market, by Application
- 10.1. Cardiology
- 10.2. Gastroenterology
- 10.3. Neurology
- 10.4. Oncology
- 10.5. Orthopedics
- 11. Digital Radiology Market, by End User
- 11.1. Ambulatory Care Centers
- 11.2. Clinics
- 11.3. Diagnostic Imaging Centers
- 11.4. Hospitals
- 12. Digital Radiology Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Digital Radiology Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Digital Radiology Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Agfa-Gevaert N.V.
- 15.3.2. Allengers Medical Systems Ltd
- 15.3.3. Analogic Corporation
- 15.3.4. Bracco Imaging S.p.A.
- 15.3.5. Canon Medical Systems Corporation
- 15.3.6. Carestream Health, Inc.
- 15.3.7. Detection Technology PLC
- 15.3.8. Esaote S.p.A.
- 15.3.9. Fujifilm Holdings Corporation
- 15.3.10. GE HealthCare Technologies Inc.
- 15.3.11. Hamamatsu Photonics K.K.
- 15.3.12. Hologic, Inc.
- 15.3.13. Imaging Dynamics Company Ltd.
- 15.3.14. Innovation Meditech Pvt. Ltd.
- 15.3.15. KA Imaging Inc.
- 15.3.16. Konica Minolta, Inc.
- 15.3.17. Koninklijke Philips N.V.
- 15.3.18. Neusoft Medical Systems Co., Ltd.
- 15.3.19. Samsung Electronics Co., Ltd
- 15.3.20. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 15.3.21. Shimadzu Corporation
- 15.3.22. Siemens Healthineers AG
- 15.3.23. Swissray, LLC
- 15.3.24. Teledyne Technologies Incorporated
- 15.3.25. Varex Imaging Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
